For research use only. Not for therapeutic Use.
ACH-000143 is a potent and orally active melatonin receptor agonist, with EC50 values of 0.06 nM and 0.32 nM for MT1 and MT2, respectively[1].
ACH-000143 reduces liver triglycerides and steatosis in diet-Induced obese rats[1].
ACH-000143 is devoid of hERG binding, genotoxicity, and behavioral alterations at doses up to 100 mg/kg p.o., supporting further investigation of this compound as a drug candidate[1].
ACH-000143 significantly reduces plasma glucose at 10 mg/kg (−16.4%, p < 0.05) and 30 mg/kg (−16.9%, p < 0.01)[1].
Catalog Number | I021284 |
CAS Number | 2225836-30-4 |
Synonyms | N-[2-(5-chloro-2,6-dimethoxybenzimidazol-1-yl)ethyl]acetamide |
Molecular Formula | C13H16ClN3O3 |
Purity | ≥95% |
InChI | InChI=1S/C13H16ClN3O3/c1-8(18)15-4-5-17-11-7-12(19-2)9(14)6-10(11)16-13(17)20-3/h6-7H,4-5H2,1-3H3,(H,15,18) |
InChIKey | BVSLRGAPRGQWNC-UHFFFAOYSA-N |
SMILES | CC(=O)NCCN1C2=CC(=C(C=C2N=C1OC)Cl)OC |
Reference | [1]. Marcos Antonio Ferreira Jr, et al. Discovery of ACH-000143: A Novel Potent and Peripherally Preferred Melatonin Receptor Agonist that Reduces Liver Triglycerides and Steatosis in Diet-Induced Obese Rats. J Med Chem. 2021 Feb 25;64(4):1904-1929. |